Biohaven Operating Income 2016-2022 | BHVN

Biohaven operating income from 2016 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Biohaven Annual Operating Income
(Millions of US $)
2021 $-704
2020 $-645
2019 $-479
2018 $-225
2017 $-108
2016 $-61
2015 $-10
Biohaven Quarterly Operating Income
(Millions of US $)
2022-09-30 $-68
2022-06-30 $-290
2022-03-31 $-54
2021-12-31 $-241
2021-09-30 $-55
2021-06-30 $-172
2021-03-31 $-236
2020-12-31 $-171
2020-09-30 $-163
2020-06-30 $-161
2020-03-31 $-151
2019-12-31 $-135
2019-09-30 $-90
2019-06-30 $-199
2019-03-31 $-54
2018-12-31 $-48
2018-09-30 $-55
2018-06-30 $-38
2018-03-31 $-83
2017-12-31 $-28
2017-09-30 $-40
2017-06-30 $-25
2017-03-31 $-14
2016-12-31 $-23
2016-09-30 $-28
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.240B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00